The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF

Takeshi Yoshida; Isamu Okamoto; Tsutomu Iwasa; Masahiro Fukuoka; Kazuhiko Nakagawa

doi:10.1016/j.febslet.2008.11.010

The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF

Takeshi Yoshida
, Isamu Okamoto
, Tsutomu Iwasa
, Masahiro Fukuoka
, Kazuhiko Nakagawa

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Cisplatin is a key agent in combination chemotherapy for various types of solid tumor. We now show that cisplatin activates signaling by the epidermal growth factor receptor (EGFR) by inducing cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Matuzumab, a monoclonal antibody to EGFR, inhibited cisplatin-induced EGFR signaling, likely through competition with the soluble form of HB-EGF for binding to EGFR. Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin. Crown

Original language	English
Pages (from-to)	4125-4130
Number of pages	6
Journal	FEBS Letters
Volume	582
Issue number	30
DOIs	https://doi.org/10.1016/j.febslet.2008.11.010
Publication status	Published - Dec 24 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Biophysics
Structural Biology
Biochemistry
Molecular Biology
Genetics
Cell Biology

Access to Document

10.1016/j.febslet.2008.11.010

Cite this

@article{792a10e45bbd40f5a1c43697c321ee70,

title = "The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF",

abstract = "Cisplatin is a key agent in combination chemotherapy for various types of solid tumor. We now show that cisplatin activates signaling by the epidermal growth factor receptor (EGFR) by inducing cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Matuzumab, a monoclonal antibody to EGFR, inhibited cisplatin-induced EGFR signaling, likely through competition with the soluble form of HB-EGF for binding to EGFR. Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin. Crown",

author = "Takeshi Yoshida and Isamu Okamoto and Tsutomu Iwasa and Masahiro Fukuoka and Kazuhiko Nakagawa",

year = "2008",

month = dec,

day = "24",

doi = "10.1016/j.febslet.2008.11.010",

language = "English",

volume = "582",

pages = "4125--4130",

journal = "FEBS Letters",

issn = "0014-5793",

publisher = "John Wiley and Sons Inc.",

number = "30",

}

TY - JOUR

T1 - The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF

AU - Yoshida, Takeshi

AU - Okamoto, Isamu

AU - Iwasa, Tsutomu

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2008/12/24

Y1 - 2008/12/24

N2 - Cisplatin is a key agent in combination chemotherapy for various types of solid tumor. We now show that cisplatin activates signaling by the epidermal growth factor receptor (EGFR) by inducing cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Matuzumab, a monoclonal antibody to EGFR, inhibited cisplatin-induced EGFR signaling, likely through competition with the soluble form of HB-EGF for binding to EGFR. Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin. Crown

AB - Cisplatin is a key agent in combination chemotherapy for various types of solid tumor. We now show that cisplatin activates signaling by the epidermal growth factor receptor (EGFR) by inducing cleavage of heparin-binding epidermal growth factor-like growth factor (HB-EGF). Matuzumab, a monoclonal antibody to EGFR, inhibited cisplatin-induced EGFR signaling, likely through competition with the soluble form of HB-EGF for binding to EGFR. Matuzumab enhanced the antitumor effect of cisplatin in nude mice harboring human non-small cell lung cancer xenografts. Our findings shed light on the mechanism by which monoclonal antibodies to EGFR might augment the efficacy of cisplatin. Crown

UR - https://www.scopus.com/pages/publications/57049094352

UR - https://www.scopus.com/pages/publications/57049094352#tab=citedBy

U2 - 10.1016/j.febslet.2008.11.010

DO - 10.1016/j.febslet.2008.11.010

M3 - Article

C2 - 19027738

AN - SCOPUS:57049094352

SN - 0014-5793

VL - 582

SP - 4125

EP - 4130

JO - FEBS Letters

JF - FEBS Letters

IS - 30

ER -

The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this